ArticlebioRxiv : the preprint server for biology2025
Boosting Transcript Assembly via Delineating Transcript Start and End Sites.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Transcript assembly remains a challenging task despite the development of numerous methods. A major contributor to low assembly accuracy is the difficulty in accurately determining transcript start sites (TSSs) and end sites (TESs), due to the weak and noisy signals typically found in RNA-seq data. We present Telos, a two-stage machine learning framework for precise detection of TSSs and TESs and for transcript ranking. The method takes as input any assembly, typically generated by an existing assembler. In the first stage, Telos scores the TSSs and TESs in the input assembly using a machine learning model trained on a rich set of engineered features. These site-level scores will be passed to the second stage for transcript-level evaluation. In its second stage, Telos scores the entire transcripts by training another model that integrates features of their TSS and TES (including the inferred probabilities from the first stage), along with transcript abundance estimated by the assembler and statistics about exon lengths. We extensively evaluated Telos on ONT (cDNA and direct RNA), PacBio, and Illumina short-read RNA-seq datasets. In all cases, it consistently outperformed baseline methods. Telos is agile, but achieves substantial improvements, demonstrating the value of explicitly modeling TSS and TES, a gap in current transcript assembly tools. Telos can be paired with any assembler to accurately score the assembled transcripts. It is modular, easily extensible to emerging sequencing technologies, and hence we anticipate its broad adoption in transcriptomic studies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.